Is Krispy Kreme a Buy After Its Latest Earnings Report?

DNUT delivered a positive earnings surprise in Q3 2026, and the numbers behind the beat point to a balance sheet repair story driven by refranchising.

The headline data: DNUT cut capital expenditures by 65%, improved free cash flow, and lowered its net leverage ratio from 6.7x to 5.5x. Wall Street analysts responded by raising price targets.

Interpretation: a 1.2-turn drop in leverage in a single stretch suggests the refranchising strategy is shifting capital burden off DNUT's books. That reads as de-risking, though 5.5x remains elevated by any standard, and the stock's upside depends on the deleveraging trend continuing.

The risks the article flags are specific. GLP-1 drugs threaten demand across the doughnut industry, and high leverage leaves little margin for error if the turnaround falters. The source characterizes the stock as speculative, and nothing in the quarter changes that label. The price target hikes show analyst sentiment improving, but they do not remove either risk.

No comparable data points for MCD or WMT appear in the supplied evidence, so this is a DNUT-specific read rather than a sector call.